Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation

JAMA

Volumn 311, Issue 11, 2014, Pages 1150-1151

  Bruins Slot, Karsten M H ^a   Berge, Eivind ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DAREXABAN; EDOXABAN; IDRAPARINUX; RIVAROXABAN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL SOCIETY; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; EMBOLISM; FACTOR XA; HUMANS; INTRACRANIAL EMBOLISM; VITAMIN K;

EID: 84896466200     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.1403     Document Type: Review

References (3)

1. Bruins Slot KMH, Berge E. Factor Xa inhibitors vs vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013;8(8):CD008980.
2. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation. Stroke. 2012;43(12):3442-3453.
3. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719-2747.